12m agoBusiness InsiderBEARISH 34General
Krystal Biotech falls as data for pipeline programs pushed to 2027
Krystal Biotech stock fell after delaying pipeline data to 2027 despite a Q3 earnings beat. Read more here.
Why Is KRYSTAL BIOTECH INC (KRYS) Stock Down Today?
By the Top Tier Newswire AI Desk · August 4, 2026 at 12:09 AM ET · reviewed against 9 wire stories
KRYSTAL BIOTECH INC (KRYS) is down -14.40% in the latest session. Our newswire has captured 9 stories on KRYS across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
KRYS stock fell 8.37% to $312.57 in the session, driven by mixed second-quarter results and investor reaction to guidance. While Krystal Biotech reported GAAP earnings per share of $1.79, which beat estimates by $0.16, revenue of $119.22 million came in $1.82 million below forecasts. The company also outlined a 2026 non-GAAP operating expense range of $175 million to $195 million, and investors appeared to weigh the revenue shortfall and evolving financial commitments.
What Happened
Krystal Biotech reported second-quarter 2026 results on August 3, 2026, with GAAP EPS of $1.79, exceeding the expected $1.63. However, revenue of $119.22 million, while up 24% year over year, fell short of the $121.06 million forecast. The company attributed the revenue miss to timing of VYJUVEK sales and the impact of Germany pricing accruals. Despite robust global VYJUVEK revenue of $119.2 million for the quarter and $965.9 million since launch, the stock declined on concerns over near-term revenue visibility and the outlined expense guidance. The firm also announced it is advancing KB801 into a pivotal trial after discontinuing a clinical study with no safety concerns observed.
What The Data Shows
Krystal Biotech ended the quarter with $1.1 billion in cash and a net margin of 53.9%. The stock has traded between $130.50 and $382.54 over the past 52 weeks. Recent insider transactions include four sales totaling $15.9 million in the last 90 days, with the most recent filing on June 26. Additionally, Donald J. Trump sold between $15,001 and $50,000 in the stock on May 15. The stock’s beta of 0.50 suggests it is less volatile than the broader market, but the sharp intraday move reflects immediate investor reaction to the earnings report and guidance.
What To Watch
The company has no upcoming earnings reports in the near term. Investors should monitor coverage breadth and analyst commentary, particularly as B of A Securities and TD Cowen have both raised price targets to $396 and $403 respectively, maintaining Buy ratings.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
KRYS by the numbers
Last: $284.43Session: -14.40%7 sessions: +3.14%Coverage: 9 stories / 5 sourcesAI sentiment: 52/100 (mixed)Mkt cap: $10.1BP/E: 45.752w: $130.50 to $382.54
The headlines behind the move
56m agoThe FlyBEARISH 34General
Krystal Biotech falls -11.7%
1h agoThe FlyBEARISH 34Analyst
Krystal pipeline catalysts experiencing delays, says RBC Capital
2h agoInvestorsHubBEARISH 42Earnings
Krystal Biotech Shares Fall 3.7% Despite Q3 Earnings Beat and 30% Revenue Growth
Krystal Biotech shares fall 3.7% despite Q3 earnings beating forecasts, with revenue up 30% to $127.34 million on strong VYJUVEK sales.
3h agoSeeking AlphaBULLISH 78Earnings
Krystal Biotech GAAP EPS of $2.05 beats by $0.28, revenue of $1.1B beats by $973.46M
Krystal Biotech Q3 earnings crushed estimates with strong EPS and revenue growth.
3h agoThe FlyBULLISH 73General
Krystal Biotech announces $400M share repurchase program
3h agoThe FlyBULLISH 63Earnings
Krystal Biotech reports Q3 EPS $2.05, consensus $1.92
3h agoSEC 8-KNEUTRAL 50General
Krystal Biotech, Inc. (KRYS) files 8-K
Filed: 2026-11-02 AccNo: 0001711279-26-000072 Size: 591 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
4h agoBusiness InsiderBULLISH 64Earnings
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results
$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed
Frequently asked questions
Why is KRYS stock down today?
KRYSTAL BIOTECH INC (KRYS) is down -14.40% in the latest session. Our newswire has captured 9 stories on KRYS across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100). The most recent driver: "Krystal Biotech falls as data for pipeline programs pushed to 2027" (Business Insider).
Is KRYS a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of KRYS coverage reads 52/100 over 9 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is PGEN down today (-25.43%)
- Why is NSSC down today (-17.26%)
- Why is IDXX up today (+16.71%)
- Why is NXT up today (+15.75%)
- Why is AXSM down today (-14.54%)
- Why is WING up today (+12.81%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on KRYS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.